• Follow
  • Follow
  • Follow
  • Follow
U

Search



Shop

w

News

w

Blog

DONATE
Team Jack Foundation
  • About Us
    • Our Mission
    • Jack Hoffman
    • Board & Staff
    • Financials
  • Our Impact
    • Scientific Advisory Board
    • Sponsored Grants
    • Research Articles
  • Brain Cancer
    • What is Brain Cancer?
      • What is DIPG?
    • Brain Cancer Facts
    • Cancer Awareness Months
      • Brain Tumor Awareness Month
    • Family Resources
  • Events
  • Get Involved
    • Fundraise
      • Host an Event
      • Run For Team Jack
      • Birthday Fundraiser
    • Give
    • Our Sponsors
    • Volunteer
  • Heroes
  • Donate
  • Shop
  • Blog
  • News
Select Page

Get Involved

Clinical Trial Finder

Search Results

Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients

Study Purpose

Purpose of the study : To evaluate the antitumoral effect of two therapeutic procedures and to evaluate their respective toxicity on the CNS.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years - 60 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Histopathologically or cytologically proven diagnostic of Primary CNS lymphoma.
  • - All histological types of non-Hodgkin's lymphoma, except MALT.
  • - Age > 18 and < 60 ans.
  • - Negative for HIV, HCV and HBV.
  • - Written informed consent -

    Exclusion Criteria:

    - Age < 18 or > 60 ans.
  • - Isolated intra-ocular lymphoma.
  • - Previous history of indolent lymphoma.
  • - Previous chemotherapy or radiotherapy for PCNSL.
  • - Isolated CNS relapse of systemic NHL.
  • - Previous history of cancer in the last 5 years, except basocellular carcinoma and non invasive cervix cancer.
  • - Renal insufficiency or creatinin clearance < 60 ml/min.
  • - Liver enzymes > 3N.
  • - Platelets < 100 000/mm3 or neutrophils < 1500/mm3) - Previous history of organ transplantation or other cause of severe immunodeficiency.
  • - Pregnancy or active sexual women with no contraception.
- Unable to follow the protocol for any reason

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT00863460
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Institut Curie
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Carole Soussain, MD
Principal Investigator Affiliation Institut Curie - Hôpital René Huguenin
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other, Industry
Overall Status Active, not recruiting
Countries France
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Primary Central Nervous System Lymphoma
Arms & Interventions

Arms

Active Comparator: A

MTX-based chemotherapy followed by WBRT

Experimental: B

MTX-based chemotherapy followed by intensive chemotherapy and hematopoietic stem cell rescue

Interventions

Radiation: - cranial radiotherapy

40 Gy

Drug: - intensive chemotherapy and hematopoietic stem cell rescue

intensive chemotherapy and hematopoietic stem cell rescue

Drug: - MTX based chemotherapy

R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58&59 and days79&80

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Cancérologie Hôpital Sud, Amiens, France

Status

Address

Cancérologie Hôpital Sud

Amiens, , 80054

Chu D'Angers, Angers, France

Status

Address

Chu D'Angers

Angers, ,

CHR Argenteuil, Argenteuil, France

Status

Address

CHR Argenteuil

Argenteuil, , 95100

CHU de Besancon, Besançon, France

Status

Address

CHU de Besancon

Besançon, ,

Institut Bergonié, Bordeaux, France

Status

Address

Institut Bergonié

Bordeaux, , 33076

CHU Hôtel Dieu, Clermont-Ferrand, France

Status

Address

CHU Hôtel Dieu

Clermont-Ferrand, ,

CHU Michalon, Grenoble, France

Status

Address

CHU Michalon

Grenoble, , 38043

Centre Hospitalier Lens, Lens, France

Status

Address

Centre Hospitalier Lens

Lens, ,

CHU de Limoges, Limoges, France

Status

Address

CHU de Limoges

Limoges, , 87042

CHU de la Timone, Marseille, France

Status

Address

CHU de la Timone

Marseille, , 13009

Hôtel Dieu Nantes, Nantes, France

Status

Address

Hôtel Dieu Nantes

Nantes, ,

Centre Antoine Lacassagne, Nice, France

Status

Address

Centre Antoine Lacassagne

Nice, ,

CHU de Nimes, Nîmes, France

Status

Address

CHU de Nimes

Nîmes, ,

GH Pitié-Salpétrière, Paris, France

Status

Address

GH Pitié-Salpétrière

Paris, , 75013

CHG Saint Jean, Perpignan, France

Status

Address

CHG Saint Jean

Perpignan, , 66046

CHU Hôpital Bernard, Poitiers, France

Status

Address

CHU Hôpital Bernard

Poitiers, , 86021

Chu Reims, Reims, France

Status

Address

Chu Reims

Reims, ,

Hôpital Pontchaillou, Rennes, France

Status

Address

Hôpital Pontchaillou

Rennes, , 35033

Centre René Huguenin, Saint Cloud, France

Status

Address

Centre René Huguenin

Saint Cloud, , 92210

Institut de Cancérologie, Saint-Priest en Jarez, France

Status

Address

Institut de Cancérologie

Saint-Priest en Jarez, ,

CH de Saint-Quentin, Saint-Quentin, France

Status

Address

CH de Saint-Quentin

Saint-Quentin, ,

Hôpital Bretonneau, Tours, France

Status

Address

Hôpital Bretonneau

Tours, ,

CHU Nancy - Hôpital Neurologique, Vandoeuvre les Nancy, France

Status

Address

CHU Nancy - Hôpital Neurologique

Vandoeuvre les Nancy, , 54500

Resources

  • Patient and Caregiver Survey
  • Clinical Trial Endpoints
  • Research Resources
Powered By

The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

Make an impact through your inbox

News, upcoming events and research updates delivered straight to your inbox.

  • This field is for validation purposes and should be left unchanged.
MAKE AN IMPACT

Donate today to help the Team Jack Foundation fund research and fight pediatric brain cancer.

Make a Donation
  • About Us
  • Our Mission
  • Jack Hoffman
  • Board & Staff
  • Fund Allocation
  • Financials
  • Our Impact
  • Scientific Advisory Board
  • Sponsored Grants
  • Research Articles
  • Brain Cancer
  • Family Resources
  • Get Involved
  • Fundraise
  • Give
  • Events
  • Our Sponsors
  • Volunteer
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow
seal of transparency badge - 2019 Gold
combined health agencies drive member charity badge
Share Omaha member badge
© 2021 Team Jack Foundation. PO Box 607, Atkinson, NE, 68713. All Rights Reserved. Team Jack Foundation, Inc. is exempt from federal income tax under section 501(c)3, ID Number 46-2301134, of the internal revenue code. All contributions to the Foundation are tax deductible. Privacy Policy • Contact